
feb pm et
summari compani largest pharmaci health care provid
price-to-earnings oper ep
risk assess reflect compani leadership
posit strong market share rel stabl
 retail drug industri off-set acquisition-integr
risk growth non-tradit competitor
fiscal year end dec ep estim base cfra
oper earn histor earn report
stk
dividend paid sinc compani report
past perform indic futur perform
reli upon
forecast reliabl indic futur perform
past perform indic futur perform reli upon
analysi prepar equiti analyst
feb pm stock trade
expect total sale rise
integr recent acquisit
billion expect net new
partial off-set lower drug price inflat
see store sale rise
benefit sever flu season earli
eas comparison second half
health plan network restrict plan
particip store base
expect ebitda margin flat
reflect shift busi mix follow
environ reduc drug reimburs
level off-set acquisit synergi
sale gener drug privat label
product help allevi margin
pressur
frozen share repurchas program
await complet aetna acquisit
result expect free cash flow use
pay debt maintain dividend
reduct effect tax rate
see
oper ep oper ep
report exclud
amort intang year
compani agre acquir third
largest health insur aetna aet
total enterpris valu billion
decemb believ combin
expect close second half
make strateg sens provid
greater abil incentiv aet million
health plan particip util caremark
mail order system retail store
complet deal pend approv also
elimin risk lose aet busi
revenu
risk recommend target price
includ greater-than-expect declin
drug reimburs feder state
govern well loss market share
within pbm servic retail pharmaci
target price appli
forward price-to-earnings multipl low end
five-year trade rang
ep estim see valuat
hurt potenti entri new competitor
lower retail prescript volum growth
slow expect ep growth due
expans restrict retail drug network
busi custom win
redistribut reproduct prohibit without written permiss copyright cfra document intend provid person invest advic take account specif invest
object financi situat particular need specif person may receiv report investor seek independ financi advic regard suitabl and/or appropri make
invest implement invest strategi discuss document understand statement regard futur prospect may realiz investor note incom
invest may fluctuat valu invest may rise fall accordingli investor may receiv back less origin invest investor seek advic concern impact
invest may person tax posit tax advisor pleas note public date document may contain specif inform longer current use make
invest decis unless otherwis indic intent updat document
corpor overview health corpor oper one largest drug store chain
pharmaci benefit manag base revenu net incom store count drug store offer
prescript drug wide assort gener merchandis includ over-the-counter drug beauti product
cosmet film photo finish servic season merchandis greet card conveni
servic plan design administr formulari manag claim process
market profil oper retail drugstor decemb state
district columbia puerto rico brazil decemb compani store top
 drug store market hold number one number two market share market
fill billion prescript account retail pharmaci
market pharmaci oper critic success view account retail
store sale end privat label brand contribut non-pharmaci sale retail
store
pharmaci servic segment provid full rang pharmaci benefit manag pbm servic
includ oper mail order pharmaci specialti pharmaci medicar part servic
formulari manag discount drug purchas agreement busi gener
billion sale total compani sale exclud interseg elimin
order pharmaci fourmail servic pharmaci
also largest oper retail health care clinic decemb oper
retail health care clinic state minuteclin name clinic diagnos treat
minor health condit perform health screen monitor chronic condit deliv vaccin
compani open new clinic acquir clinic decemb
corpor strategi retail store compani aim improv custom access care
help lower overal health care cost improv health outcom result addit fill
prescript retail pharmacist increas focu provid servic flu
vaccin in-person counsel addit mani possibl interact
custom retail store websit pharmaci servic mail specialti pharmaci
call center compani strive influenc plan member behavior lower cost improv
impact major develop compani acquir pharmaci busi consist
locat in-stor health clinic decemb approxim billion
clinic purchas re-brand minuteclin addit open new clinic within
store end addit plan develop five small format
store two-year period follow close transact
compani acquir omnicar prescript drug servic provid long-term health
specialti healthcar industri total enterpris valu billion august see ep
accret reflect signific synergi revenu purchas improv
compani acquir coram llc specialti infus servic enter nutrit busi apria
healthcar group billion januari
financi trend sale grew compound annual growth rate driven
net new pharmaci servic busi win acquisit low singl digit store sale growth
ebitda margin narrow slightli form reflect increas drug
reimburs pressur nevertheless normal ep grew five-year compound-annual-growth-rate support
share repurchas
execut vice
gener counsel
redistribut reproduct prohibit without prior written permiss copyright cfra
base cfra proprietari quantit model
stock rank overvalu
analysi stock current worth base
cfra proprietari quantit model suggest
under-valued
neutral sinc februari technic indic
neutral
figur base fiscal year-end price
growth rate averag
lt debt capit
return equiti
balanc sheet data million
oper
long term debt capit
net incom revenu
return asset
return equiti
 global market intellig data may preliminari restat result discontinu operations/speci item per share data adjust stock dividend ep dilut
redistribut reproduct prohibit without prior written permiss copyright cfra
prescript front-end sale servic
expand
year date decemb
compar rise
industri index declin
compar increas
think under-perform
reimburs pressur slow in-stor
traffic trend due increas competit
despit increas demand favor
demograph age babi boomer
expand health care coverag
neutral fundament outlook
drug retail sub-industri next month
see sale continu benefit
increas demand age babi boomer
see margin benefit increas gener drug
purchas power improv sale leverag
howev see margin expans limit
intens drug reimburs pressur
increas competit non-tradit
compani within retail drug industri
well posit view benefit
increas prescript drug usag
develop privat loyalti card
program prescript volum like rise
age babi boomer nearli
util prescript drug addit
reflect conveni locat close
consum home retail drugstor better
posit take market share
non-tradit competitor expans
loyalti card program like help support
increas basket size traffic reflect
person shop experi
custom also loyalti program like
help support retail margin due improv
market promot spend effici
expect near-term advers
impact potenti chang health care
legisl long-term demand would
restrict peopl lose health care
coverag also expect prescript revenu
growth somewhat limit next
month due convers brand drug
lower-pr gener drug near-term peak
benefit sale gener drug
occur believ gener
drug sale acceler slightli
also see in-stor health clinic offer
increasingli help drive store traffic
base index
five-year market price perform feb
note sector sub-industri inform base
past perform indic futur perform
reli upon
yield equiti
ltd
peer group compani stock select issu base market capit
note peer select base global industri classif standard market capit peer group list includ compani similar characterist may includ compani within
industri and/or engag line busi
redistribut reproduct prohibit without prior written permiss copyright cfra
ep restrict drug reimburs pressur growth restrict
drugstor network ep vs estim
store sale fell narrow expect see pressur weak
traffic trend restrict pharmaci network pharmaci
servic result line estim /joseph agnes
et cfra lower opinion share aetna hold
strong buy accord unconfirm report includ
wall street journal made bid acquir aet
combin would integr larg pharmaci benefit
manag pbm health insur effort control drug
price surpris potenti merger due success
pbm unit optum recent announc
form pbm though note partnership
rais target price approxim potenti offer
accord numer unconfirm media report talk
acquir aetna aet third largest health insur
believ combin make strateg sens provid greater
abil incentiv aet million health plan particip util
caremark mail order system retail store see benefit
deal would also elimin futur risk lose aet busi
contribut cvss consolid net revenu /joseph
et cfra keep hold opinion share
corpor lower target
price-to-earnings low end rang forward ep
estim see valuat pressur drug reimburs pressur
retail share loss lift ep estim ep
vs estim compar store sale fell
narrow expect reflect restrict pharmaci
network lower promot spend pharmaci servic client retent
strong billion net new busi thu far season
analyst research note compani news
et cfra keep hold opinion share
corpor rais target
price-to-earnings low end rang ep estim
see valuat pressur industri price pressur
set ep ep vs
estim store sale growth estim benefit
sever flu season plan use tax benefit boost spend
employe data analyt servic offer see pressur
margin addit debt reduct ahead expect acquisit
februari health corpor announc helena foulk
execut vice presid leav employ compani effect
et cfra keep hold opinion share aetna inc
keep target price rais ep estim
set stand-alon basi aid
tax reform aet indic acquisit remain
track expect close subject approv ep
vs estim sale declin primarili due
lower membership aet aca-compli individu small group product
aet medic benefit ratio increas bp medic membership
total million decemb /jeffrey loo cfa
et cfra keep buy opinion share group
amazon jp morgan berkshir hathaway announc
partnership form independ healthcar compani serv employe
although time detail compani form still unclear
compani state focu use technolog solut drive
cost past year amazon rumor interest
enter drug distribut market share healthcar compani
express script significantli morn
believ prematur due lack detail time /jeffrey loo
et cfra keep hold opinion share aetna inc
aet agre acquir
consist cash share aet share
deal subject approv expect close although
see anti-trust scrutini believ merger receiv approv
much busi overlap rais target
approxim offer price believ combin pbm unit
increas combin compani leverag better control cost
combin compani sale ebitda /jeffrey loo
et cfra keep hold opinion share
corpor agre acquir third largest
health insur aetna aet billion cash
share per aet share believ deal expect close
make strateg sens provid greater abil
incentiv aet million health plan particip util caremark
mail order system retail store see low- mid-single-digit ep
accret within two year deal complet pend approv
combin also elimin risk lose aet busi
sale /joseph agnes
et cfra keep hold opinion share caremark
cut target price-to-earnings low
end cvss rang ep estim
see valuat pressur potenti entri new competitor
note research note reflect cfra publish opinion analysi stock time note publish note reflect view equiti analyst date time
indic note may reflect cfra current view compani
redistribut reproduct prohibit without prior written permiss copyright cfra
fiscal year analyst estim earn
usd quarter fiscal year
announc earn per share usd repres
total revenu estim fiscal year
analyst estim earn per share grow
usd
total
estimate
forecast reliabl indic futur perform
note compani earn outlook play major part invest decis global market intellig organ earn estim wall street analyst
provid consensu earn next two year well earn estim chang time note inform provid relat consensu
estim intend predict actual result taken reliabl indic futur perform
note tabl graph chart report cite refer sourc sourc global market intellig
redistribut reproduct prohibit without prior written permiss copyright cfra
p/nav price net asset valu ratio price-to-earnings-to-growth ratio pv present
 research develop roce return capit employ roe
return equiti
roi return invest
 return invest capit
roa return asset
wacc weight averag capit
dividend american depositori receipt adr american depositori
share adss net tax paid countri origin
reflect equiti analyst view given compani oper risk
risk firm abil continu on-going concern qualit risk
assess rel rank star univers
reflect risk factor relat compani oper oppos risk
volatil measur associ share price etf reflect
capitalization-weight basi averag qualit risk assess
assign hold fund
star rank system definit
total return expect outperform total return relev benchmark
notabl margin come month share rise price
total return expect outperform total return relev benchmark
come month share rise price absolut basi
total return expect close approxim total return relev
benchmark come month share gener rise price
absolut basi
total return expect under-perform total return relev
benchmark come month share price anticip
total return expect under-perform total return relev
benchmark notabl margin come month share fall
price absolut basi
north america relev benchmark europ
asia relev benchmark europ asia
sinc januari cfra equiti fund research servic
predecessor capit iq equiti research rank univers
common stock adr american depositari receipt adss american
depositari share base given equiti potenti futur perform
similarli rank asian european equiti sinc june
rank equiti accord individu forecast equiti futur total
return potenti versu expect total return relev benchmark
region index asia europ
base time horizon star design meet need
investor look put invest decis perspect data use
assist determin star rank may result analyst
model well intern proprietari model result dynam data
also known
 growth
stabil earn dividend deem key element establish
global market intellig earn dividend rank common stock
design capsul natur record singl symbol
note howev process also take consider certain
adjust modif deem desir establish rank
final score stock measur score matrix determin
analysi score larg repres sampl stock
rang score array sampl align follow
ladder rank
cfra earn per share ep estim reflect analyst project futur
ep continu oper gener exclud variou item
view special non-recur extraordinari also ep estim reflect
either forecast equiti analyst consensu averag ep estim
independ compil global market intellig data
provid cfra among item typic exclud ep estim
asset sale gain impair restructur merger-rel charg legal
insur settlement process research develop expens gain
loss extinguish debt cumul effect account
chang earn relat oper classifi
compani discontinu inclus item stock option
expens recur type charg may vari depend
factor industri practic analyst judgment extent
type data disclos compani
equiti analyst project market price given secur command
month henc base combin intrins rel privat
cfra equiti research produc distribut account research
analyt llc d/b/a cfra cfra us togeth affili
subsidiari cfra certain research produc distribut standard
 poor malaysia sdn bhd cfra malaysia certain research distribut
cfra uk limit cfra uk cfra uk cfra malaysia wholly-own
subsidiari cfra us
abbrevi use equiti research report
ebit earn interest tax
redistribut reproduct prohibit without prior written permiss copyright cfra
